The Rese Journal · The Science
Semaglutide helps the heart at any age or fitness level
A major 2026 analysis found the heart-protective benefits held regardless of how frail or fit a person was — and the frailest patients often felt the greatest improvement in their daily life.
Gary A. Smith, MD, MMM, DABFMChairman & Chief Medical Officer — board-certified family physician, 25+ years
Aging, extra weight, and heart disease can make anyone feel like their best health is behind them. New research delivers a hopeful message: it may not be. A major analysis published in JAMA Cardiology in 2026 found that semaglutide protected the hearts of adults with cardiovascular disease and overweight or obesity no matter how frail or robust they were to begin with — and, remarkably, often helped the frailest people feel the most improvement in their day-to-day quality of life.
The big picture
Semaglutide is a GLP-1 medication originally developed for type 2 diabetes that has since shown meaningful weight loss and — critically — heart protection. In the landmark SELECT trial, which enrolled more than 17,600 adults with established heart disease and overweight or obesity but without diabetes, weekly semaglutide lowered the risk of major heart events — cardiovascular death, non-fatal heart attack, and non-fatal stroke — by about 20% compared with placebo (Lincoff et al., New England Journal of Medicine, 2023).
That was already a landmark result. The newest question researchers asked was more personal: Does this benefit still hold if a person is frail?
What "frailty" means — and why the question matters
Frailty is a measure of how much wear and tear the body has accumulated — reduced strength, slower recovery, multiple health conditions stacking up. It's not the same as age; some younger people are frail, some older people are not. Historically, frail patients have often been left out of clinical trials or considered "too fragile" for newer treatments, leaving many people and their families wondering whether a promising therapy is really meant for them.
What the new study found
Researchers took the SELECT trial data and sorted participants into three groups based on a 31-item frailty score — most robust to most frail. Here is what they found (Ostrominski et al., JAMA Cardiology, 2026):
1
The heart benefit held across the board. Semaglutide reduced major heart events consistently whether a person was not frail, moderately frail, or most frail. Statistically, there was no meaningful difference in benefit between the groups.
2
The protection went beyond heart attacks and strokes. Semaglutide also reduced heart failure–related events, hospitalizations for any cause, and death from any cause — again, regardless of frailty level.
3
The frailest people often felt the most improvement in quality of life. Gains in day-to-day well-being tended to be greater in those who started out more frail.
4
Frailty itself improved. Over about two years, people taking semaglutide were more likely to become less frail and less likely to become more frail compared with those taking placebo.
5
It was well tolerated in frail patients. Frailty did not lead to more people stopping the medication because of side effects.
Being frail was not a reason to expect less from this treatment. If anything, some of the people with the most to overcome experienced some of the most encouraging changes.
How semaglutide works
Semaglutide mimics a natural gut hormone called GLP-1. It signals the brain to reduce appetite and increase fullness, slows how quickly the stomach empties, and helps the body handle blood sugar. The result is meaningful, sustained weight loss for many people.
But the heart benefits appear to be more than weight loss alone. Researchers have found that semaglutide's protection begins early — before large amounts of weight are lost — and holds even in people whose weight or waistline changes only modestly (Deanfield et al., The Lancet, 2025). This has led scientists to describe GLP-1 medications as potential disease-modifying treatments for the heart, working through effects on inflammation, blood vessels, and metabolism — not just the number on the scale.
Why this matters
For a long time, the message to older or frailer adults with heart disease was one of limitation. This research flips that script. It suggests that meaningful improvement — a stronger heart, more good days, and even a reduction in frailty itself — is possible for a much wider range of people than many assumed. Your starting point does not have to define where you can go.
The short version
- Semaglutide reduced major heart events by ~20% in the SELECT trial — in 17,600+ adults with heart disease and overweight/obesity.
- A 2026 analysis confirmed those benefits held equally across all frailty levels.
- The frailest patients often saw the greatest gains in day-to-day quality of life.
- Frailty itself improved — people were more likely to become less frail over two years.
- GLP-1 medications appear to protect the heart through mechanisms beyond weight loss alone.
This article is for general education and isn't medical advice, diagnosis, or treatment. The SELECT trial studied adults with established cardiovascular disease and overweight or obesity without diabetes — your own situation may differ, which is why a personalized evaluation matters. Semaglutide is a prescription medication, appropriate only when determined by a licensed provider. Every treatment decision at Rese is made by a licensed provider who has reviewed your individual health history. Individual results vary.